Safety and Efficacy of TSHA-102 in Adult Females With Rett Syndrome (REVEAL Adult Study)

Rett Syndrome Clinical Trial

Official title:

Open-label, Randomized, Dose-escalation and Dose-expansion Study of the Safety and Preliminary Efficacy of a Single Intrathecal Administration of TSHA-102, an AAV9-Delivered Gene Therapy, in the Treatment of Adult Females With Rett Syndrome

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05606614
• Other study ID #: TSHA-102-CL-101
• Status: Recruiting
• Phase: Phase 1/Phase 2
• Start date: March 6, 2023
• Est. completion date: January 5, 2032

Study information

• Verified date: March 2024
• Source: Taysha Gene Therapies, Inc.
• Contact: Taysha Gene Therapies Medical Information
• Phone: 833-489-8742
• Email: medinfo[@]tayshagtx.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The REVEAL Adult Study is a multi-center, Phase 1/2 open-label, dose-escalation study of TSHA-102, an investigational gene therapy, in adult females with Rett syndrome. The safety, tolerability, and preliminary efficacy of two dose levels will be evaluated.

The study duration is estimated to be up to 63 months.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 18
• Est. completion date: January 5, 2032
• Est. primary completion date: November 8, 2024
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 12 Years and older

Eligibility

Inclusion Criteria:

• Participant has a clinical diagnosis of classical/typical Rett syndrome with a documented pathogenic mutation of the methyl-CpG-binding protein 2 (MECP2) gene that results in loss of function.

• Participants must be willing to receive blood or blood products for the treatment of an AE if medically needed.

Exclusion Criteria:

• Participant has another neurodevelopmental disorder independent of the MECP2 loss-of-function mutation, or any other genetic syndrome with a progressive course.

• Participant has a history of brain injury that causes neurological problems.

• Participant had grossly abnormal psychomotor development in the first 6 months of life.

• Participant has a diagnosis of atypical Rett syndrome.

• Participant has a MECP2 mutation that does not cause Rett syndrome.

• Participant requires invasive ventilatory support.

• Participant has contraindications for IT administration of TSHA-102 or lumbar puncture procedure, or other medical conditions, or contraindications to any medications required for IT administration.

• Participant has uncontrolled seizures or a history of status epilepticus within the 3 months prior to enrollment.

Related Conditions & MeSH terms

• Rett Syndrome
• Syndrome

Intervention

Genetic:
• TSHA-102
TSHA-102 is a recombinant, non-replicating, self-complementary AAV9 (scAAV9) vector encoding for the miniMECP2 gene. TSHA-102 is a one-time intrathecal (IT) administration.

Locations

Country	Name	City	State
Canada	Taysha Study Site	Montréal
United States	Rush University Medical Center	Chicago	Illinois

Sponsors (1)

Lead Sponsor	Collaborator
Taysha Gene Therapies, Inc.

Countries where clinical trial is conducted

United States,  Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Proportions of participants experiencing any treatment-emergent adverse events (AEs) and serious adverse events (SAEs)		Baseline through Week 52
Primary	Change from baseline in participant's status after TSHA-102 administration as assessed by Clinical Global Impressions-Improvement (CGI-I) scale, adapted to Rett syndrome		Baseline through Week 52
Primary	Change from baseline in participant's status after TSHA-102 administration as assessed by the Revised Motor Behavior Assessment (R-MBA)		Baseline through Week 52
Primary	Change from baseline in participant's status after TSHA-102 administration as assessed by the Rett Syndrome Hand Function Scale (RSHFS)		Baseline through Week 52
Secondary	Change from Baseline in participant's status after TSHA-102 administration as assessed by Clinical Global Impressions-Severity (CGI-S)		Baseline through Week 52
Secondary	Change from baseline in monthly seizure frequency (52 weeks)		Baseline through Week 52
Secondary	Change from baseline in adaptive behavior as assessed by Vineland-3		Baseline through Week 52
Secondary	Change from Baseline in quantitative EEG findings with visual evoked potentials		Baseline through Week 52
Secondary	Change from Baseline in quantitative EEG findings with auditory evoked potentials		Baseline through Week 52